NMD Pharma A/S

NMD Pharma A/S is a clinical-stage biotech company focused on developing life-changing therapies for neuromuscular diseases. Their mission is to develop novel treatments to improve muscle function and quality of life for patients with neuromuscular disease. They aim to create a future where patients with neuromuscular diseases live better and more independent lives. The company has a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need. NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis. Established in 2015 and headquartered in Aarhus, Denmark, the company has more than 25 employees with expertise in all areas of drug development. They collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases. NMD Pharma recently received a €75.00M Series B investment on 15 November 2023 from investors including Novo Holdings, Jeito Capital, Roche Venture Fund, Inkef, and Lundbeckfonden Emerge. For more information, please visit the company website.